FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/11/2024
Back to search
Official data from USPTO
CELAID THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Quick snapshot
ST13
US500000079347683Class
1, 5, 40, 42, 44
Filing
79347683
Registration
7324426
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
08/11/2024
Trademark type
Combined
Nice classes
1, 5, 40, 42, 44
Filing date
05/18/2022
Registration date
03/12/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/12/2024
Last transaction
03/12/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
JP
Examiner
CASE, LEIGH
Law office
M30
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "CELAID" with the letters "CELA" and "D" in black and the letter "I" in pink. The stylized word "THERAPEUTICS" appears below in black. To the left of the wording, the design of two irregular circles appears, with the lower circle in pink and the upper circle in blue. The overlapping area of the circles appears in purple.
Holders and representatives
Holders
Celaid Therapeutics Inc.
Representatives
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical reagents for non-medical purposeschemicals for use in the manufacture of pharmaceuticals; reagents for scientific and research use
Class 5
Pharmaceutical preparations for the prevention and treatment of cancers; pharmaceutical preparations for the prevention and treatment of hematological malignancies; pharmaceutical preparations for the prevention and treatment of non-hematological malignancies; pharmaceutical preparations for the prevention and treatment of genetic disorders; pharmaceutical preparations for use as gene therapy agent; pharmaceutical preparations for use as regenerative medicine agent; cells for medical use; blood products for the prevention and treatment of cancers; blood products for the prevention and treatment of hematological malignancies; blood products for the prevention and treatment of non-hematological malignancies; blood products for the prevention and treatment of genetic disorders; blood products for use as gene therapy agent; blood products for use as regenerative medicine agent; blood for medical purposes; hemotropic agents for stimulation of cell functiongene therapycell therapyfor use as blood substitutes; cellular function activating agents for medical purposes; reagents for medical use; cell preparations for the treatment of diseases and disorders; clinical diagnostic reagents; stem cells for medical purposes
Class 40
Treatment and processing of human cells for others; treatment and processing of cells for medical use; cryogenic preservation; custom manufacture of pharmaceutical preparations for others; treatment and processing of blood and blood products
Class 42
Testinginspection or research of pharmaceuticalscosmetics or foodstuffs
Class 44
Blood testing and analysis; provision of information on blood tests; providing medical information and consultation; blood bank services; rental of blood filtration units; medical services relating to the removaltreatment and processing of human bloodumbilical cord bloodhuman cellsstem cells and bone marrow
Publications
History of USPTO decisions and trademark events.
28 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/19/2024
FIMP
FINAL DISPOSITION PROCESSED
07/19/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/13/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/12/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/13/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/24/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/24/2024
GPNX
NOTIFICATION PROCESSED BY IB
12/26/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/26/2023
PUBO
PUBLISHED FOR OPPOSITION
12/26/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/06/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/06/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/01/2023
RFNT
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/01/2023
RFRR
REFUSAL PROCESSED BY MPU
05/01/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/11/2023
CNRT
NON-FINAL ACTION WRITTEN
03/10/2023
DOCK
ASSIGNED TO EXAMINER
03/08/2023
MAFR
APPLICATION FILING RECEIPT MAILED
08/23/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/19/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/18/2022
Continuous trademark protection
Get notified about every new filing that threatens CELAID THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.